Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.
Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects.
Immunovirology Laboratory, Biomedicine Institute of Seville (IBiS), Infectious Diseases Service, Virgen del Rocío University Hospital, Sevilla, Spain.
Miguel
M
Genebat
Hospital Santa María del Rosell-Santa Lucía, Cartagena, Spain.
Francisco
F
Vera
Hospital Universitario San Cecilio, Granada, Spain.
José
J
Hernández-Quero
Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain.
Pere
P
Domingo
Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain.
José M
JM
Guardiola
Hospital Santa María del Rosell-Santa Lucía, Cartagena, Spain.
Onofre
O
Martínez-Madrid
Hospital Santa María del Rosell-Santa Lucía, Cartagena, Spain.
Lorena
L
Martínez
Hospital Perpetuo Socorro, Badajoz, Spain.
Francisco García
FG
de la Llana
Hospital Comarcal de la Merced, Osuna, Sevilla, Spain.
Jorge
J
Sánchez-Villegas
Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, Health Area of Ferrol, A Coruña, Spain.
Hortensia
H
Alvarez
Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, Health Area of Ferrol, A Coruña, Spain.
Ana
A
Mariño
Hospital Dr José Molina Orosa, Lanzarote, Spain.
José F
JF
Lluch
Hospital Universitario San Cecilio, Granada, Spain.
María A
MA
Martínez-Pérez
Hospital Perpetuo Socorro, Badajoz, Spain.
Jorge
J
Marín
Immunovirology Laboratory, Biomedicine Institute of Seville (IBiS), Infectious Diseases Service, Virgen del Rocío University Hospital, Sevilla, Spain.
Ezequiel
E
Ruiz-Mateos
Immunovirology Laboratory, Biomedicine Institute of Seville (IBiS), Infectious Diseases Service, Virgen del Rocío University Hospital, Sevilla, Spain. Electronic address: mleal@telefonica.net.
Manuel
M
Leal
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
D000998:Antiviral Agents; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir; D007372:Interferons
HIV; Hepatitis C virus; Liver cirrhosis; Telaprevir